Randomized controlled trials with time-to-event outcomes:: How much does prespecified covariate adjustment increase power?

被引:51
作者
Hernández, AV [1 ]
Eijkemans, MJC [1 ]
Steyerberg, EW [1 ]
机构
[1] Erasmus MC, Dept Publ Hlth, Ctr Clin Decis Sci, NL-3000 DR Rotterdam, Netherlands
关键词
statistical data interpretation; computer simulation; covariate; power; proportional hazards models; randomized controlled trials; sample size;
D O I
10.1016/j.annepidem.2005.09.007
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PURPOSE: We evaluated the effects of various strategies of covariate adjustment on type I error, power, and potential reduction in sample size in randomized controlled trials (RCTs) with time-to-event outcomes. METHODS: We used Cox models in simulated data sets with different treatment effects (hazard ratios [HRs] = 1, 1.4, and 1.7), covariate effects (HRs = 1, 2, and 5), covariate prevalences (10% and 50%), and censoring levels (no, low, and high). Treatment and a single covariate were dichotomous. We examined the sample size that gives the same power as an unadjusted analysis for three strategies: prespecified, significant predictive, and significant imbalance. RESULTS: Type I error generally was at the nominal level, The power to detect a true treatment effect was greater with adjusted than unadjusted analyses, especially with prespecified and significant-predictive strategies. Potential reductions in sample size with a covariate HR between 2 and 5 were between 15% and 44% (covariate prevalence 50%) and between 4% and 12% (covariate prevalence 10%). The significant imbalance strategy yielded small reductions. The reduction was greater with stronger covariate effects, but was independent of treatment effect, sample size, and censoring level. CONCLUSIONS: Adjustment for one predictive baseline characteristic yields greater power to detect a true treatment effect than unadjusted analysis, without inflation of type I error and with potentially moderate reductions in sample size. Analysis of RCTs with time-to-event outcomes should adjust for predictive covariates.
引用
收藏
页码:41 / 48
页数:8
相关论文
共 29 条
[1]  
Akazawa K, 1997, STAT MED, V16, P583, DOI 10.1002/(SICI)1097-0258(19970315)16:5<583::AID-SIM433>3.0.CO
[2]  
2-Z
[3]  
ANDERSON GL, 1995, BIOMETRIKA, V82, P527, DOI 10.1093/biomet/82.3.527
[4]  
BEACH ML, 1989, CONTROL CLIN TRIALS, V10, pS161
[5]   Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study [J].
Bonnefoy, E ;
Lapostolle, F ;
Leizorovicz, A ;
Steg, G ;
McFadden, EP ;
Dubien, PY ;
Cattan, S ;
Boullenger, E ;
Machecourt, J ;
Lacroute, JM ;
Cassagnes, J ;
Dissait, F ;
Touboul, P .
LANCET, 2002, 360 (9336) :825-829
[6]   PLACEBO-CONTROLLED TRIAL OF SAFETY AND EFFICACY OF INTRAOPERATIVE CONTROLLED DELIVERY BY BIODEGRADABLE POLYMERS OF CHEMOTHERAPY FOR RECURRENT GLIOMAS [J].
BREM, H ;
PIANTADOSI, S ;
BURGER, PC ;
WALKER, M ;
SELKER, R ;
VICK, NA ;
BLACK, K ;
SISTI, M ;
BREM, S ;
MOHR, G ;
MULLER, P ;
MORAWETZ, R ;
SCHOLD, SC .
LANCET, 1995, 345 (8956) :1008-1012
[7]   COVARIATE ADJUSTMENT OF TREATMENT EFFECTS IN CLINICAL-TRIALS [J].
CANNER, PL .
CONTROLLED CLINICAL TRIALS, 1991, 12 (03) :359-366
[8]   A QUANTITATIVE STUDY OF THE BIAS IN ESTIMATING THE TREATMENT EFFECT CAUSED BY OMITTING A BALANCED COVARIATE IN SURVIVAL MODELS [J].
CHASTANG, C ;
BYAR, D ;
PIANTADOSI, S .
STATISTICS IN MEDICINE, 1988, 7 (12) :1243-1255
[9]   Clinical trials in the new millennium [J].
DeMets, DL .
STATISTICS IN MEDICINE, 2002, 21 (19) :2779-2787
[10]   Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAL randomised trial [J].
Dickstein, K ;
Kjekshus, J .
LANCET, 2002, 360 (9335) :752-760